Tim Clackson, Theseus CEO

Or­biMed's TKI play makes its Nas­daq de­but as The­seus prices IPO

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

A Boston biotech with a hefty back­ing from Or­biMed is mak­ing its Nas­daq de­but Thurs­day.

The­seus Phar­ma­ceu­ti­cals priced its IPO at $16 per share, the high end of its range, jump­ing to the pub­lic mar­ket rough­ly six months af­ter Or­biMed led the biotech’s nine-fig­ure Se­ries B. The­seus net­ted $160 mil­lion for the pub­lic of­fer­ing, bring­ing the sec­tor’s to­tal com­bined 2021 raise to $13.74 bil­lion across 86 dif­fer­ent com­pa­nies, per the End­points News tal­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.